Aandeel HCM HUTCHMED (CHINA) LIMITED
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen HUTCHMED (China) Limited Nasdaq

Aandelen

HCM

US44842L1035

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 17-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
17,88 USD -1,32% Intraday-grafiek van HUTCHMED (China) Limited +0,68% -1,27%
17/06 Hutchmed viert "veelbelovende" resultaten voor sovleplenib in China AN
10/06 Transcript : HUTCHMED Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Hutchmed celebrates "promising" results for sovleplenib in China
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
Hutchmed (China) begins trial of menin inhibitor HMPL-506
Hutchmed Begins Phase 1 Trial of Potential Treatment for Acute Myeloid Leukemia
Hutchmed (China)'a Cancer Drug Phase I Clinical Trial Begins
HUTCHMED Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HUTCHMED Limited Announces Results from FRUTIGA, HUTCHMED's Phase III Trial of Fruquintinib in Combination with Paclitaxel for the Treatment of Second-Line Advanced Gastric Cancer
HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be presented at the upcoming EHA2024 Congress
Hutchmed (China) Chairman Resigns, Successor Named
Hutchmed China Simon To leaves role, succeeded by Dan Eldar
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor
HUTCHMED Limited Announces Executive Changes
Hutchmed (China) to Present Sovleplenib Phase III Data at EHA2024 Congress
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers HCM
  4. Koers HCM
  5. Nieuws HUTCHMED (China) Limited
  6. Andere talen